Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
about
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactionsImpact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease control.Estimation of α/β for late rectal toxicity based on RTOG 94-06The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trialsHDR Brachytherapy in the Management of High-Risk Prostate Cancer.Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking.Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-upManagement of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.Predictive models in external beam radiotherapy for clinically localized prostate cancer.Intensity-modulated radiotherapy (IMRT) to prostate and pelvic nodes-is pelvic lymph node coverage adequate with fiducial-based image-guided radiotherapy?Toxicity of tomotherapy-based simultaneous integrated boost in whole-pelvis radiation for prostate cancerIntensified adjuvant treatment of prostate carcinoma: feasibility analysis of a phase I/II trialClinical outcome and toxicity evaluation of simultaneous integrated boost pelvic IMRT/VMAT at different dose levels combined with androgen deprivation therapy in prostate cancer patients.Postoperative radiotherapy for prostate cancer : Morbidity of local-only or local-plus-pelvic radiotherapy.
P2860
Q34048630-7A3E58B7-5105-47B4-8569-CE195EA4E90AQ34187079-2B6DD531-4B72-4C0E-B533-7DDDCC50DDA5Q34998545-1E9A8638-4A05-4601-BD8B-91DBEF852C67Q35186584-64FC9914-4D55-4B6A-B4AF-9242327F9EB5Q35680859-0D71C6A4-8E55-4F74-AC78-D187A82ACBEAQ35810413-FBBE1C20-E17B-460F-972E-3AA54ECFA923Q35992601-7733A3EE-548C-412C-81BE-1C3DE709827EQ36617012-70F55B53-9F1B-4B8F-A40B-74D4DB531C50Q37035229-70DBF4B0-5FC4-444D-A530-093604DA57C4Q37081939-E972FFDD-8550-4AF8-9645-CCE00FDDA69BQ37086178-652B9E16-B5BB-4DF2-81C8-D17693241646Q37480893-EF9BCB78-3E27-4DE6-8A11-360BA0011817Q37526758-F37F86D8-910C-4D74-9F9A-E391C8174EC3Q41490932-C792641A-B11E-4033-B9D4-5189FD500E44Q41994836-DDBADA05-24FF-4FB6-AE19-EC9D46C89593Q42571904-F635FFB8-2E1B-4CF3-B4BA-15DF72CE6B94Q42687909-9A3B41E3-AA46-483C-8B8C-3280D7F395A3Q50002077-36E4EB7E-9C7E-4EFD-A181-378567B20F01
P2860
Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Re: The use of prostate specif ...... ith localized prostate cancer.
@en
Re: The use of prostate specif ...... ith localized prostate cancer.
@nl
type
label
Re: The use of prostate specif ...... ith localized prostate cancer.
@en
Re: The use of prostate specif ...... ith localized prostate cancer.
@nl
prefLabel
Re: The use of prostate specif ...... ith localized prostate cancer.
@en
Re: The use of prostate specif ...... ith localized prostate cancer.
@nl
P1476
Re: The use of prostate specif ...... ith localized prostate cancer.
@en
P2093
P304
P356
10.1016/S0022-5347(17)35937-2
P407
P577
1993-12-01T00:00:00Z